The anticonvulsant retigabine is a subtype selective modulator of GABA<sub>A</sub> receptors

Marco Treven, Xaver Koenig, Elham Assadpour, Enkhbileg Gantumur, Christiane Meyer, Karlheinz Hilber, Stefan Boehm, and Helmut Kubista

Epilepsia, 56(4):647–657, 2015
doi: 10.1111/epi.12950

**Summary**

**Objective:** Within its range of therapeutic plasma concentrations, the anticonvulsant retigabine (ezogabine) is believed to selectively act on Kv7 channels. Here, the contribution of specific γ-aminobutyric acid (GABA)<sub>A</sub> receptor subtypes to the antiseizure effects of retigabine was investigated.

**Methods:** Using patch-clamp recordings, seizure-like activity, tonic currents, and GABA-induced currents in hippocampal neurons were tested for their sensitivity toward retigabine, as were recombinant GABA<sub>A</sub> receptors expressed in tsA 201 cells.

**Results:** Retigabine reduced seizure-like activity elicited by low Mg<sup>2+</sup> in a concentration-dependent manner with half maximal inhibition at 1 μM. Seizure-like activity triggered by blocking either Kv7 channels or GABA<sub>A</sub> receptors was equally reduced by retigabine, but when these channels/receptors were blocked simultaneously, the inhibition was lost. Retigabine (10 μM) enhanced bicuculline-sensitive tonic currents in hippocampal neurons, but failed to affect GABA-evoked currents. However, when receptors involved in phasic GABAergic inhibition were blocked by penicillin, retigabine did enhance GABA-evoked currents. In tsA 201 cells expressing various combinations of GABA<sub>A</sub> receptor subunits, 10 μM retigabine enhanced currents through α1β2, α4β2, α4β3, and α6β2 receptors, but left currents through α1β2γ2S, α4β3γ2S, α5β3γ2S, and α6β2γ2S receptors unaltered. With αβ receptors, retigabine diminished currents through α1β2 and α4β3, but increased currents through α6β2 receptors. The enhancement of currents through α1β2 receptors by retigabine was concentration dependent and became significant at 1 μM.

**Significance:** These results demonstrate that retigabine is a subtype selective modulator of GABA<sub>A</sub> receptors with preference for extrasynaptic α-containing receptors; this property may contribute to its broad antiepileptic effectiveness and explain its lack of effect on absence seizures.

**KEY WORDS:** Retigabine, Seizure-like activity, Kv7 channels, Extrasynaptic GABA<sub>A</sub> receptors.

Although an armamentarium of antiepileptic drugs has been available for half a century, seizures have remained uncontrolled in a considerable proportion of patients. Therefore, at least a dozen new antiepileptic drugs have been introduced within the past 20 years, many of which act via newly identified molecular targets. The avenue toward target identification with respect to antiepileptic pharmacotherapy is guided by the increasing knowledge regarding genetic epilepsies. Most of the mutations responsible for the development of seizures affect genes coding for various ion channels. Among such genes, the KCNQ family is a
prominent group. KCNQ genes code for proteins that are pore-forming subunits of Kv7 channels. In the nervous system, these channels activate at subthreshold potentials, give rise to noninactivating potassium currents, and thereby stabilize the membrane potential.³ Conceivably, loss-of-function mutations in these channels may lead to hyperexcitability of the affected neurons and thus to seizure-like activity. Supporting this notion, activators of Kv7 channels have been developed to be used in conditions of neuronal hyperexcitability, such as pain and epilepsy.⁴ In the 1990s, retigabine, also known as ezogabine, had been found to exert potent anticonvulsant activity in a broad range of seizure models and to activate K⁺ channels in neurons and neuron-like cells.⁵ In 2011, retigabine was finally approved for the treatment of partial seizures in adults⁶ and is now viewed as the first-in-class antiepileptic K⁺ channel opener.⁷

Mutations in Kv7 channels have been identified as the molecular basis for benign familial neonatal seizures (BFNS).⁸ These are multifocal tonic–clonic convulsions that typically emerge during the second or third postnatal day and disappear spontaneously after a few weeks or months.² In light of this transient nature of seizures caused by mutations in Kv7 channels, it appears somewhat unexpected that an activator of these channels, such as retigabine, can provide sustained anticonvulsive activity. In fact, the spontaneous resolution of BFNS has been explained by the maturation of the central nervous system, in particular by the developmental switch of the γ-aminobutyric acid (GABA)ergic system from excitatory to inhibitory.⁹ The inhibitory control of neuronal output by GABAergic neurons plays a pivotal role in orchestrating neuronal circuits to properly fulfill their physiologic functions,⁹ and potentiation of the GABAergic neurotransmission is the oldest mechanism of action known for antiepileptic drugs.¹

GABAergic inhibition involves GABA_A and GABA_B receptors, the former being pentameric ligand-gated ion channels composed of 1–4 different types of subunits of a repertoire of at least 19 proteins.¹⁰ When activated by GABA, these receptors conduct currents carried by Cl⁻ and HCO₃⁻ ions, and such currents present themselves in two fundamentally different ways, as phasic and tonic currents, respectively. These different types of currents are mediated by separate sets of GABA_A receptors, namely synaptic and extrasynaptic receptors, which are characterized by distinct molecular architectures; synaptic receptors contain γ subunits, whereas most extrasynaptic receptors integrate δ subunits instead.¹¹,¹²

Retigabine opens Kv7 channels at concentrations of 1–6 μM.⁷ At 10 μM or above, retigabine has also been found to affect GABA_A receptors,¹³,¹⁴ but this action is considered to be irrelevant with respect to its anticonvulsant effectiveness.⁷ Moreover, it is not known whether retigabine might differentiate between synaptic and extrasynaptic GABA_A receptors. This study uses an in vitro model of seizure-like activity to reveal that retigabine’s anticonvulsive activity involves Kv7 channels as well as GABA_A receptors and demonstrates that therapeutic concentrations of this drug act selectively on a subset of extrasynaptic GABA_A receptors.

**Methods**

**Cell cultures and transfections**

Primary cultures of hippocampal neurons were prepared as described in detail before.¹⁵ Tissue was obtained from Sprague-Dawley rats, which were killed by decapitation in full accordance with all rules of the Austrian animal protection law (see http://www.ris.bka.gv.at/Dokumente/BgbIAuth/BGBLA_2012_I_114/BGBLA_2012_I_114.pdf) and the Austrian animal experiment by-laws (see http://www.ris.bka.gv.at/Dokumente/BgbIAuth/BGBLA_2012_I_522/BGBLA_2012_I_522.pdf) which implement European (DIRECTIVE 2010/63/EU; see http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:276:0033:0079:en:PDF) into Austrian law (all information accessed on July 2, 2014). The responsible animal welfare body is the “Ethics Committee of the Medical University of Vienna for Research Projects Involving Animals.” For the measurement of seizure-like activity and tonic currents, cultures of hippocampal neurons were used >20 days after dissociation to ensure the establishment of fully functional synaptic contacts and thus proper neuronal networks.¹⁵ For GABA-evoked currents, cultures were used after about 10 days.¹⁶

For heterologous expression of GABA_A receptors and Kv7 channels, tSA 201 cells (a subclone of human embryonic kidney 293 cells) were cultured in Dulbecco’s modified Eagle’s medium containing 1 g/L glucose and 10% heat-inactivated fetal calf serum. Cells were transfected using ExGen 500 or Turbofect according to the manufacturer’s recommendations, with a transfection ratio of 1:1 for αβ receptors, 1:1:8 for αβγ or αβδ receptors, and 1:1 for heteromeric Kv7.2/Kv7.3 channels. The day after transfection, cells were seeded at lower density into 35-mm culture dishes and used for patch-clamp recordings 24–48 h after transfection.

**Electrophysiology**

All recordings were done at room temperature (20–24°C). Patch pipettes were made with a Sutter P97 horizontal puller (Sutter Instruments, Novato, CA, U.S.A.) using borosilicate glass capillaries (GB150-8P; Science Products, Hofheim, Germany). Tip resistances were between 2 and 5 MΩ. Recordings were performed using the perforated patch method, with the exception of tonic currents for which the whole-cell configuration was used instead. For perforated patch measurements, pipettes were front filled with internal solution and then back filled with the same solution containing 500 μg/mL amphotericin B. Recordings were started after 20–30 min when series resistance had dropped and stabilized below 20 MΩ.
Current clamp recordings of seizure-like activity were performed using a Multiclamp 700B amplifier (Molecular Devices, Sunnyvale, CA, U.S.A.) as described before. The internal (pipette) solution for current clamp recordings contained (mM): 120 potassium gluconate, 1.5 sodium gluconate, 3.5 NaCl, 1.5 CaCl₂, 0.25 MgCl₂, 10 2-(4-(2-hydroxyethyl)-1-piperazinyl)-ethansulfonic acid (HEPES), 10 glucose, and 5 ethylene glycol tetraacetic acid (EGTA) (pH was adjusted to 7.3 with KOH). The external bathing solution consisted of (mM): 140 NaCl, 3 KCl, 2 CaCl₂, 2 MgCl₂, 10 HEPES, and 20 glucose (pH was adjusted to 7.4 with NaOH). For low Mg²⁺ conditions, MgCl₂ was omitted from the external solution. Alternatively, 30 µM XE991 and/or 30 µM biccuculline methiodide was added to induce seizure-like activity.

For voltage clamp recordings, an Axopatch 200B amplifier was used. For the determination of tonic currents, the internal solution was composed of (mM): 135 CsCl, 10 HEPES, 10 EGTA, and 1 MgCl₂ (adjusted to pH 7.3 with CsOH). For GABA-evoked currents, the internal solution contained (mM): 140 KCl, 2 CaCl₂, 0.7 MgCl₂, 10 EGTA, and 10 HEPES (pH was adjusted to 7.3 with KOH). For currents through Kv7 channels, the internal solution was composed of (mM): 75 K₂SO₄, 55 KCl, 8 MgCl₂, 10 HEPES (adjusted to pH 7.3 with KOH). In all voltage clamp recordings, the external solution consisted of (mM): 140 NaCl, 20 glucose, 10 HEPES, 2.5 CaCl₂, 2 MgCl₂, and 3 KOH (pH was adjusted to 7.4 with NaOH). For the recording of tonic currents, 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, 10 µm) and tetrodotoxin (1 µm) were added to suppress glutamatergic neurotransmission and action potential propagation, respectively.

For the recording of GABA-evoked currents, cells were continuously superfused, and drugs were applied using a piezo-switched fast-step SF-77B perfusion connected to an eight-channel valve control VC-8 System (Warner Instruments, Hamden, CT, U.S.A.). GABA currents were elicited by application of GABA for 3 s to cells clamped at −70 mV. Currents through Kv7 channels were elicited by depolarizing cells to −30 mV; once every 10 s, cells were hyperpolarized to −55 mV for 1 s periods to allow the channels to close and to observe the deactivation current during these hyperpolarizations, which is specific for the Kv7 channels; currents were quantified by measuring amplitudes observed at −30 mV.

**Data analysis and statistics**

Seizure-like activity in current clamp recordings involves enhanced discharge frequencies as well as depolarized membrane potentials and was thus quantified by determining area under the curve (AUC) values as described. Briefly, the area between the voltage trace and a baseline corresponding to the average resting membrane potential before onset of seizure-like activity, was calculated (mV·msec) for periods of 90 s per condition. AUC values in the presence of retigabine were calculated as percentage of averaged AUC values obtained before and after the application of the drug. Amplitudes of tonic currents in voltage clamp recordings were averaged for periods of 3 s, and differences between amplitudes determined before and after the addition of bicuculline were calculated.

GABA-evoked currents were assessed by means of peak amplitudes. For concentration response curves of GABA-induced currents in the presence of either solvent or drugs, current amplitudes evoked by different GABA concentrations in solvent or drugs were normalized to that of a normalization current evoked by 100 or 300 µM GABA in solvent in the very same cell. To determine the effects of retigabine on currents evoked by a fixed GABA concentration, this selected GABA concentration was applied for 3 s in the continuous presence of either solvent or retigabine; amplitudes in the presence of solvent/retigabine were calculated as percentage of mean control GABA current amplitudes obtained before and after the application of solvent/retigabine, respectively. Statistical analysis and preparation of graphs was done with the GraphPad Prism 5.0 software (Graphpad Software Inc, La Jolla, CA, U. S. A). Concentration response data were fitted using the Hill equation. All values are presented as mean ± standard error of the mean (SEM), unless indicated otherwise. Significance levels are given as n.s. not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, with the statistical test and number of repetitions appropriately indicated in the text or figure legends.

**Drugs and materials**

Rat GABAₐ receptor subunit complementary DNAs (cDNAs) were generously provided by Werner Sieghart, Margot Ernst, and Petra Scholze (Center for Brain Research, Vienna, Austria), and plasmids for Kv7.2 and Kv7.3 channels by Mark Shapiro (San Antonio, TX, U.S.A.). Retigabine was obtained from Alomone (Jerusalem, Israel); tetrodotoxin (TTX) from Laotroxan (Valence, France); GABA, kynurenic acid, XE 991, biccuculline methiodide, 6-cyano-7-nitroquinoxaline-2,3-dione disodium salt (CNQX), putrescine, progesterone, poly-D-lysine, cytosine arabinoside, amphotericin B, as well as bulk chemicals from Sigma-Aldrich (Vienna, Austria); and insulin, transferrin, and Na-selenite from Roche (Mannheim, Germany). Dulbecco’s modified Eagle’s medium, Leibovitz L-15 medium, penicillin, streptomycin and L-glutamine were purchased from PAA Laboratories (Pasching, Austria). Papain was bought from Worthington (Lakewood, NJ, U.S.A.). Heat-inactivated fetal calf serum was obtained from Invitrogen (Lofer, Austria). ExGen and Turbofect reagents were obtained from Fermentas (St. Leon-Rot, Germany). Culture dishes were obtained from Nunc (Roskilde, Denmark).
RESULTS

Suppression of seizure-like activity by retigabine involves both Kv7 channels and GABAA receptors

In rat hippocampal slices, the experimental paradigm of seizure-like activity induced by low Mg2+ has been used before to provide evidence for the antiseizure activity of retigabine: 20–100 μM of the drug reduced seizure-like events.21 This, however, is beyond therapeutic concentrations, which range up to 10 μM only.22 In primary cultures of dissociated rat hippocampi with well-established synaptic contacts (i.e., at least 20 days in culture), low Mg2+ can also be used to trigger seizure-like activity,17 and the latter was reduced by retigabine in a concentration-dependent manner with half maximal inhibition at 1 μM (Fig. 1A,E).

The anticonvulsive action of retigabine is assumed to be based on its ability to open Kv7 channels.7 Despite this

Figure 1.
Effects of retigabine on seizure-like activity and tonic currents in cultured hippocampal neurons. Seizure-like activity was induced by low extracellular Mg2+ (Mg2+-free solution), XE 991, or bicuculline (bic) applied either alone or together. (A–D) Original recordings of seizure-like activity induced by low Mg2+ (A), 30 μM XE 991 (B), 30 μM bicuculline (bic; C), or XE 991 plus bicuculline (D). Traces were obtained before (left) and during (right) the presence of 3 μM retigabine (ret). Scale bars: 1 s. Dashed lines refer to the average membrane potential prior to the induction of seizure-like activity. (E) Concentration–response curve for the inhibition of seizure-like activity induced by low Mg2+ (orange) in the presence of the indicated concentrations of retigabine. This inhibition was evaluated by the reduction of the area under the curve (AUC), which was half maximal at 1.3 ± 0.3 μM (n = 7). The inhibitory effect of 3 μM retigabine was also quantified for seizure-like activity induced by XE 991 (red), bicuculline (bic; green), or XE 991 plus bicuculline (green-blue). AUC values obtained with XE 991 plus bicuculline were significantly different from all other values at p < 0.0001 (n = 7–9; one-way analysis of variance [ANOVA] with Bonferroni’s multiple comparison correction). (F) Holding currents recorded in one neuron at a potential of −70 mV in the presence of solvent, 10 μM retigabine, and 30 μM bicuculline (bic), respectively; bicuculline was first added in the presence of solvent and then in the presence of retigabine, as indicated by the bars. The graph shows differences in current amplitudes (Δ amplitude) measured before and after the addition of bicuculline for seven neurons; *p < 0.05 (Wilcoxon matched pairs signed-rank test).
post, the inhibitory effect of 3 μM retigabine remained unchanged when seizure-like activity was induced by 30 μM XE 991 instead of low Mg²⁺ (Fig. 1B,E), the former being an irreversible inhibitor of Kv7 channels.²³ To prove that the effect of retigabine on seizure-like activity induced by XE 991 could not be mediated by an action on Kv7 channels, the combination of these two agents was tested on recombinant Kv7.2/Kv7.3 channel heteromers expressed in tsA 201 cells. The nonactivating currents through these channels determined at a potential of −30 mV were enhanced reversibly in the presence of 10 μM retigabine to 153.6 ± 7.3% of control values (n = 14). The subsequent application of 10 μM XE 991 reduced these current amplitudes to 5.0 ± 1.1% of control (n = 14; p < 0.05; analysis of variance followed by Dunn’s multiple comparison test). Thereafter, the addition of retigabine (10 μM) to XE 991 left current amplitudes unchanged (5.1 ± 1.2% of control; n = 14; p > 0.05). After removal of both drugs, current amplitudes also remained suppressed (7.2 ± 1.2% of control; n = 13). Thus, in the presence of XE 991, retigabine is unable to open Kv7 channels. Therefore, its action on seizure-like activity must have involved alternative mechanisms.

As high concentrations (>10 μM) of retigabine had been reported to act on GABAₐ receptors,¹³,¹⁴ the GABAₐ receptor antagonist bicuculline methiodide was used at saturating concentrations (30 μM)²⁴ to trigger seizure-like activity. Three micromolar retigabine reduced seizure-like activity caused by bicuculline methiodide to the same extent as seizure-like activity triggered by either low Mg²⁺ or XE 991 (Fig. 1C,E). However, when seizure-like activity was induced by XE 991 plus bicuculline, the inhibitory action of 3 μM retigabine was lost (Fig. 1D,E). Thus, the antiseizure activity of retigabine appears to involve both Kv7 channels and GABAₐ receptors.

**Retigabine enhances bicuculline-sensitive tonic currents**

In voltage clamp recordings in cultures that displayed seizure-like activity, retigabine (10 μM) was found to shift holding currents determined at −70 mV (not shown). To reveal whether such an effect might also occur independently of Kv7 channels, recordings were performed using the whole cell configuration with intracellular Cs⁺ to block K⁺ channels. Under these conditions, 10 μM retigabine enhanced standing inward currents (Fig. 1F). Such tonic currents involve continuous activity of extrasynaptic GABAₐ receptors, which can be blocked by bicuculline.²⁵ Here, bicuculline reduced amplitudes of tonic inward currents as expected (Fig. 1D). However, differences in tonic current amplitudes caused by 30 μM bicuculline were significantly larger in the presence of retigabine (59.7 ± 21.7 pA) than in the presence of solvent (45.0 ± 18.8 pA; p < 0.05 Wilcoxon matched pairs signed-rank test). Thus, bicuculline-sensitive tonic currents were enhanced by retigabine.

**Blockage of receptors involved in phasic GABAergic inhibition reveals an effect of low retigabine concentrations on GABAₐ receptors**

At concentrations of 10 μM and above, retigabine has been found to enhance inhibitory postsynaptic currents as well as GABA-evoked currents in cortical neurons. In hippocampal neurons lacking functional synaptic GABAergic input, as used here, GABA-induced currents were not affected by 10 μM retigabine (Fig. 2A,B). In hippocampal neurons, 5 mM penicillin has been shown to block phasic GABAergic inhibition without affecting tonic inhibition.²⁶ Here, 5 mM penicillin reduced GABA-induced currents in a noncompetitive manner (Fig. 2C,D). Moreover, GABA-evoked currents in the presence of penicillin were enhanced by 10 μM retigabine (Fig. 2E,F). Thus, retigabine exerted a facilitatory effect on GABAₐ receptors when receptors involved in phasic GABAergic inhibition were blocked.

At low GABA concentrations, current amplitudes are very small (Fig. 2F) and easily biased by time-dependent changes in experimental conditions as well as by eventual minute contaminations by saturating GABA concentrations. Therefore, in additional experiments we specifically tested for the effects of 10 μM retigabine at low GABA concentrations; 1 μM GABA was applied in the presence of 5 mM penicillin plus solvent and of 5 μM penicillin plus 10 μM retigabine, respectively. Amplitudes in the presence of 10 μM retigabine (129.7 ± 3.7% of control; n = 7) were significantly larger than those in the presence of solvent (102.1 ± 3.4% of control; n = 7; p < 0.01; paired t-test subsequent to a Kolmogorov-Smirnov test).

**Retigabine preferentially acts on GABAₐ receptors containing δ subunits**

Tonic GABAergic inhibition is mediated by extrasynaptic GABAₐ receptors, which do not contain γ subunits, but most frequently δ.¹¹,¹² To explore a potential subtype selective action of retigabine, several subunit combinations typical for synaptic (α₁β₂γ₂S) and extrasynaptic (α₁β₂δ, α₄β₃δ, α₅β₃γ₂S, and α₆β₂δ) GABAₐ receptors were expressed in tsA 201 cells and currents through these receptors were determined. Retigabine (10 μM) enhanced the currents through the δ-containing receptors, but left the currents through the γ-containing receptors unaltered (Fig. 3D,G–I; Table 1). To investigate this apparent subtype selectivity in a more systematic manner, the δ subunits in α₁β₂δ, α₄β₃δ, and α₆β₂δ were replaced by γ₂S. Consistently, retigabine only potentiated δ (Fig. 3G–I), but not γ₂S-containing receptors (Fig. 3D–F). For comparison, the above combinations of α and β subunits were also expressed without either γ₂S or δ subunits. In these receptors, retigabine (10 μM) caused an inhibition of α₁β₂ and α₄β₃, but a facilitation of α₆β₂ (Fig. 3A–C). With all these receptors, retigabine affected only the maxima of the concentration response curves for GABA-induced currents, but left the concentrations required for

---

Epilepsia, 56(4):647–657, 2015
doi: 10.1111/epi.12950
half maximal current activation (EC$_{50}$) unaltered (Table 1). To reveal whether the type of β subunit incorporated into the receptors also plays a role, the effect of 10 μM retigabine was compared for α4β2δ and α4β3δ, but no significant differences were observed (Table 1).

To specifically test for the effects of 10 μM retigabine on currents evoked by low GABA concentrations in the recombinant receptors, 1 mM GABA was applied to α1β2δ and α4β3δ receptors in the continuous presence of either solvent or retigabine. As with the native receptors above, amplitudes in the presence of 10 μM retigabine (α1β2δ: 125.9 ± 9.0% of control; n = 5; α4β3δ: 119.5 ± 8.0% of control; n = 6) were significantly larger than those in the presence of solvent (α1β2δ: 100.3 ± 0.7% of control; n = 5; p < 0.01; α4β3δ: 99.1 ± 1.6% of control; n = 6; p < 0.05; paired t-test subsequent to a Kolmogorov-Smirnov test).

**Concentration dependence of the effects of retigabine on GABA$_A$ receptors**

To reveal in which concentration range retigabine may affect the GABA$_A$ subunit combinations described earlier, currents through α1β2δ and α1β2δ receptors were triggered by GABA concentrations causing half maximal current amplitudes (i.e., 2 and 6 μM, respectively) in the presence of different retigabine concentrations. A significant increase in the amplitudes of currents through the α1β2δ receptor was found at concentrations as low as 1 μM (Fig. 4C,D). For the inhibition of currents through α1β2δ receptors, higher concentrations were required (Fig. 4A,B).

**Discussion and Conclusions**

Opening of neuronal Kv7 channels is regarded the sole mechanism of action of the novel antiepileptic drug retiga-
Retigabine and δ-Containing GABA<sub>A</sub> Receptors

Figure 3.
Effects of retigabine on GABA-evoked currents in tsA 201 cells expressing various combinations of GABA<sub>A</sub> receptor subunits. Currents through α1β2 (A), α4β3 (B), α6β2 (C), α1β2/2S (D), α4β3/2S (E), α6β2/2S (F), α1β2δ (G), α4β3δ (H), and α6β2δ (I) receptors were evoked by the application of the indicated concentrations of GABA in the presence of solvent (control; black) or 10 μM retigabine (blue). For original sample traces see Figure 4A,C. For the concentration–response curves, all peak current amplitudes determined in one cell were normalized to the amplitude of the current triggered by 300 μM GABA in the presence of solvent. Data were fitted to a Hill equation; parameters are given in Table 1.

Epilepsia © ILAE

Retigabine and δ-containing GABA<sub>A</sub> receptors. Its anticonvulsive activity was confirmed using the well-established in vitro paradigm of seizure-like activity induced by low Mg<sup>2+</sup>. In these experiments, retigabine reduced neuronal firing in a concentration-dependent manner with half maximal effects at about 1 μM. This drug is known to cause half-maximal activation of homo- as well as heteromeric Kv7 channels in a similar concentration range. Unexpectedly, this inhibitory effect of retigabine was the same when seizure-like activity was triggered by blocking Kv7 channels with XE 991. In addition, seizure-like activity induced by the GABA<sub>A</sub> receptor antagonist bicuculline was reduced to the same extent by retigabine. However, when Kv7 channels and GABA<sub>A</sub> receptors were blocked simultaneously, the inhibitory action of retigabine was lost. Moreover, retigabine (10 μM) enhanced tonic currents when K<sup>+</sup> channels were blocked by intracellular Cs<sup>+</sup>, and this effect was bicuculline sensitive. These results suggest GABA<sub>A</sub> receptors as alternative therapeutic targets for retigabine and led us to investigate the interactions between these receptors and the antiepileptic drug in detail.

Previously, retigabine has been reported to increase the amplitudes and to prolong the decay of inhibitory postsynaptic currents in mouse cortical neurons. Retigabine has also been shown to reduce GABA release from rat hippocampal synaptosomes, but this latter action appeared to lack in the study on mouse cortical neurons. In any case,
effects of retigabine on GABAergic neurotransmission may involve presynaptic as well as postsynaptic effects, the former ones being most likely mediated by an action on Kv7 channels.\textsuperscript{27} In the present study, confounding effects arising at a presynaptic site of action were avoided by the two following measures: (1) by activating the receptors through exogenous application of GABA and (2) by using hippocampal neurons lacking functional synaptic GABAergic input. Under these conditions, 10 \textmu M retigabine did not affect currents through GABA\textsubscript{A} receptors.

In cultured hippocampal neurons, GABAergic inhibition occurs in two major forms, phasic and tonic inhibition, and the former can be prevented by penicillin.\textsuperscript{26} When receptors involved in phasic inhibition were blocked by penicillin, GABA-evoked currents were potentiated by 10 \textmu M retigabine. Thus, retigabine appears to selectively act on receptors mediating tonic GABAergic inhibition. Phasic GABAergic inhibition is mediated by synaptic GABA\textsubscript{A} receptors, tonic inhibition by extrasynaptic ones; the latter contain mostly \(\delta\) instead of \(\gamma\) subunits.\textsuperscript{11,12} Despite this disparity in receptor composition, the differential effect of penicillin on phasic and tonic GABAergic inhibition\textsuperscript{20} is not due only to subunit specificity of the antibiotic. Even though penicillin causes less inhibition in \(\delta\)-containing than in \(\gamma\textsubscript{2}\)-containing receptors, the preferential block of phasic inhibition is also related to the conditions of receptor activation: currents evoked by high GABA concentrations are reduced to a greater extent than currents elicited by lower concentrations, and peak current amplitudes are efficiently diminished, whereas steady state current levels are hardly affected.\textsuperscript{28} Thus, the results obtained in hippocampal neurons in the presence of penicillin do not permit unequivocal conclusions regarding the GABA\textsubscript{A} receptor subtype preference of retigabine.

The most prevailing extrasynaptic GABA\textsubscript{A} receptors are composed of the following subunits: \(\alpha 1\beta\delta\) in hippocampal and cortical interneurons; \(\alpha 4\beta\delta\) in thalamic relay neurons, hippocampal dentate granule cells, and cortical pyramidal neurons in addition to medium spiny neurons in the striatum; \(\alpha 6\beta 2\delta\) in cerebellar granule cells; and \(\alpha 5\beta 2\gamma 2\) in hippocampal and cortical pyramidal neurons.\textsuperscript{11,12} Previously, a structural analogue of retigabine (AA29504) has been found to display differing actions at \(\alpha 1\beta 3\gamma 2\) and \(\alpha 4\beta 3\delta\) receptors.\textsuperscript{29} In the present study, retigabine enhanced currents through all recombinant GABA\textsubscript{A} subunit combinations containing \(\delta\), but left currents through all the tested \(\gamma 2\)-containing receptors unaltered. In particular, \(\alpha 1\beta 2\), \(\alpha 4\beta 2\), \(\alpha 4\beta 2\gamma 2\) and \(\alpha 6\beta 2\delta\) were potentiated by retigabine, and the \(\gamma 2\)-containing counterparts were not affected. Some of the extrasynaptic GABA\textsubscript{A} receptors in hippocampal neurons may consist of \(\alpha\) subunits only.\textsuperscript{30} With receptors containing solely \(\alpha 3\) subunits, the effect of retigabine appeared to depend on the \(\alpha\) subunit: currents through \(\alpha 1\beta 2\) and \(\alpha 4\beta 3\) receptors were reduced, whereas those through \(\alpha 6\beta 2\) were enhanced by the antiepileptic drug. Because \(\alpha 6\) subunits are not present in the hippocampus,\textsuperscript{31} the enhancement of GABA-evoked currents in the cultured neurons is most likely due to the facilitatory effect on \(\delta\)-containing receptors.

At recombinant Kv7 channels, retigabine concentrations required for half maximal current enhancement lie in the low micromolar range.\textsuperscript{7} When widely varying concentrations of retigabine were tested for their effects on recombinant GABA\textsubscript{A} receptors, a statistically significant enhancement of currents through \(\delta\)-containing receptors was found at concentrations as low as 1 \textmu M. High retigabine concentrations led to a dramatic current enhancement of more than fourfold, but a saturation of the effect was not reached, which prevents a reliable calculation of values for half maximal effects. In pharmacokinetic studies, retigabine plasma concentrations in humans reached 5 \textmu M.\textsuperscript{32} Similar concentrations were also achieved in clinical tri-

### Table 1. Hill equation parameters for GABA concentration–response relations of currents through various recombinant GABA\textsubscript{A} receptors in the presence of either solvent or 10 \textmu M retigabine

| Isoform | Solvent | Retigabine (10 \textmu M) |
|---------|---------|-------------------------|
|         | EC\textsubscript{50} (\textmu M) | E\textsubscript{max} (normalized) | EC\textsubscript{50} (\textmu M) | E\textsubscript{max} (normalized) |
| \(\alpha 1\beta 2\) | 2.30 ± 0.19 | 0.98 ± 0.02 | 1.93 ± 0.22 n.s. | 0.62 ± 0.01*** |
| \(\alpha 1\beta 2\)/\(\gamma 2\) | 22.19 ± 2.19 | 1.05 ± 0.03 | 27.92 ± 10.91 n.s. | 1.17 ± 0.16 n.s. |
| \(\alpha 1\beta 2\)/\(\delta\) | 6.37 ± 0.82 | 1.01 ± 0.03 | 6.01 ± 0.67 n.s. | 1.66 ± 0.04*** |
| \(\alpha 4\beta 3\) | 1.45 ± 0.33 | 0.99 ± 0.03 | 1.55 ± 0.65 n.s. | 0.77 ± 0.05* |
| \(\alpha 4\beta 3\)/\(\gamma 2\) | 32.05 ± 3.22 | 1.10 ± 0.04 | 23.32 ± 5.54 n.s. | 1.09 ± 0.08 n.s. |
| \(\alpha 4\beta 3\)/\(\delta\) | 0.16 ± 0.07 | 1.02 ± 0.06 | 0.32 ± 0.14 n.s. | 1.17 ± 0.07** |
| \(\alpha 4\beta 2\) | 1.43 ± 0.13 | 1.00 ± 0.01 | 1.26 ± 0.25 n.s. | 1.19 ± 0.04*** |
| \(\alpha 5\beta 2\)/\(\gamma 2\) | 5.66 ± 1.41 | 1.04 ± 0.06 | 5.57 ± 1.76 n.s. | 0.97 ± 0.07 n.s. |
| \(\alpha 5\beta 2\)/\(\delta\) | 0.74 ± 0.13 | 1.02 ± 0.02 | 1.37 ± 0.44 n.s. | 1.61 ± 0.08*** |
| \(\alpha 6\beta 2\)/\(\gamma 2\) | 3.55 ± 0.81 | 1.02 ± 0.05 | 4.60 ± 1.31 n.s. | 0.95 ± 0.06 n.s. |
| \(\alpha 6\beta 2\)/\(\delta\) | 0.53 ± 0.02 | 0.99 ± 0.02 | 0.67 ± 0.19 n.s. | 1.68 ± 0.07*** |

Concentration–response curves of currents through the listed GABA\textsubscript{A} receptor isoforms were obtained in the presence of either solvent or 10 \textmu M retigabine (*F* test: \(n = 4–10\); n.s. = no significant difference, *p < 0.05, **p < 0.01, ***p < 0.001 vs. the corresponding values in the presence of solvent). Representative concentration–response curves are displayed in Figure 3.
Given that the plasma protein binding of the drug amounts to about 80%, free plasma concentrations can be expected to be around 1 μM. Although levels of retigabine in the human brain remain unknown, the drug has been shown to accumulate in the brain of rodents. This cerebral accumulation was dose dependent and more than sixfold in comparison with plasma concentrations, when doses of ≥2 mg per kg body weight (corresponding to human doses of >150 mg) had been applied to rats. Thus, therapeutic levels of retigabine in the brain can be expected to reach values as high as 10 μM and to be sufficient to modulate Kv7 channels as well as δ-containing GABA_α receptors.

The perception of δ-containing GABA_α receptors as therapeutic targets for retigabine leads to the pathophysiology of such receptors in epilepsy. In various models of temporal lobe epilepsy, δ subunit expression and functions of extrasynaptic GABA_α receptors undergo complex changes. Loss of neurosteroids that activate δ-containing GABA_α receptors increases seizure frequency, whereas overexpression and activation of extrasynaptic GABA_α receptors reduces seizure-like activity in vitro and in vivo, respectively. Extrasynaptic receptors display high affinities for GABA and are activated by low ambient GABA concentrations. These latter concentrations are controlled by GABA reuptake and metabolism, and these two mechanisms are suppressed by tiagabine and vigabatrin, respectively, two antiepileptic drugs in clinical use for about two decades. Although these agents lead to an activation of extrasynaptic GABA_α receptors indirectly through an increase in GABA concentrations, one of the most recently developed antiepileptic drugs, ganaxolone, directly activates the receptors and prefers δ containing over other types of GABA_α receptors. Hence, preferential activation of δ-containing

Figure 4.
Retigabine concentration–response relation for GABA-evoked currents through α1β2 or α1β2δ GABA_α receptors expressed in tsA 201 cells. Currents were evoked by the application of either 2 μM (A and B) or 6 μM (C and D) GABA (the EC50 values for α1β2 and α1β2δ receptors, respectively; see Table 1), in the presence of either solvent or the indicated concentrations of retigabine (ret). (A, C) Original traces of currents evoked by GABA in a cell expressing either α1β2 (A) or α1β2δ (C). (B, D) Concentration–response curves for the effect of retigabine on GABA-induced currents in cells expressing either α1β2 (B; orange) or α1β2δ (D; red). Peak current amplitudes determined in the presence of the indicated concentrations of retigabine were normalized to the amplitudes obtained in the presence of solvent (n = 8). * , ** , *** indicate significant differences versus the amplitudes obtained in the presence of solvent at p < 0.05, p < 0.001, and p < 0.0001, respectively.

Epilepsia © ILAE
GABA<sub>A</sub> receptors is an established mechanism of action in antiepileptic pharmacotherapy. This, however, does not hold true for all types of seizures. Enhanced activity of extrasynaptic GABA<sub>A</sub> receptors in thalamocortical neurons is a common pathophysiologic mechanism in several models of absence epilepsy, and absence seizures are exacerbated by drugs that activate δ-containing GABA<sub>A</sub> receptors. Retigabine has been found to be effective in virtually all types of seizure models, with the notable exception of absence seizures, even though Kv7 channels are highly expressed in the thalamus. Thus, the selective action of retigabine on δ-containing versus other GABA<sub>A</sub> receptors may not only contribute to its broad spectrum of antiepileptic effectiveness, but also explain its hitherto inexplicable lack of effect in absence seizures.

**ACKNOWLEDGMENTS**

We thank Ulla Schandl for her help with experiments regarding seizure-like activity in hippocampal cultures. The perfect technical assistance by Gabriele Gaupmann is greatly acknowledged. This study was supported by the Austrian Science Fund (FWF; project numbers W1205, P23658 and P23670); MT is member of the doctoral program CCHD funded by FWF and the Medical University of Vienna.

**DISCLOSURE**

None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

**REFERENCES**

1. Löscher W, Klitgaard H, Twyman RE, et al. New avenues for antiepileptic drug discovery and development. *Nat Rev Drug Discov* 2013;12:757–776.
2. Hellbig I, Scheffer IE, Mulley JC, et al. Navigating the channels and the Medical University of Vienna. *Epilepsia* 2005;46:620–628.
3. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. *Rev Drug Discov* 2008;7:231–245.
4. Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. *Eur J Pharmacol* 2009;582:16–25.
5. Grunnet M, Strobaek D, Hougaard C, et al. Kv7 channels as targets for anti-epileptic and psychiatric drug development. *Eur J Pharmacol* 2014;726:133–137.
6. Rundfeldt C. The new anticonvulsant retigabine (D-23129) acts as an opener of K<sup>+</sup> channels in neuronal cells. *Eur J Pharmacol* 1997;336:243–249.
7. Stafstrom CE, Grippon S, Kirkpatrick P. Ezogabine (retigabine). *Nat Rev Drug Discov* 2011;10:729–730.
8. Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K<sup>+</sup> channel opener for the treatment of epilepsy. *Epilepsia* 2012;53:412–424.
9. Solodovieri MV, Miceli F, Tagliatela M. Driving with no brakes: molecular pathophysiology of Kv7 potassium channels. *Physiology (Bethesda)* 2011;26:365–376.
10. Klausberger T, Somogyi P. Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. *Science* 2008;321:53–57.
11. Olsen RW, Sieghart W. GABA A receptors: subtypes provide diversity of function and pharmacology. *Neuropharmacology* 2009;56:141–148.
12. Farrant M, Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. *Nat Rev Neurosci* 2005;6:215–229.
13. Brickley SG, Mody I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. *Neuron* 2012;73:23–34.
14. Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. *Arzneimittel-Forschung* 2000;50:1063–1070.
15. Otto JF, Kimball MM, Wilcox KS. Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission. *Mol Pharmacol* 2002;61:921–927.
16. Geier P, Lagler M, Boehm S, et al. Dynamic interplay of excitatory and inhibitory coupling modes of neuronal L-type calcium channels. *Am J Physiol Cell Physiol* 2011;300:C937–C949.
17. Klinger F, Geier P, Dorostkar MM, et al. Concomitant facilitation of GABAA receptors and KV7 channels by the non-opioid analgesic flupirtine. *Br J Pharmacol* 2012;166:1631–1642.
18. Rubi L, Schandl U, Lagler M, et al. Raised activity of L-type calcium channels renders neurons prone to form paroxysmal depolarization shifts. *Neuromolecular Med* 2013;15:476–492.
19. Boehm S. Selective inhibition of M-type potassium channels in rat sympathetic neurons by uridine nucleotide preferring receptors. *Br J Pharmacol* 1998;124:1261–1269.
20. Sarto-Jackson I, Milenkovic I, Smalla K-H, et al. The cell adhesion molecule neuroplastin-65 is a novel interaction partner of γ-aminobutyric acid type A receptors. *J Biol Chem* 2012;287:14201–14214.
21. Li Y, Ganner N, Hilgemann DW, et al. Regulation of Kv7 (KCNQ) K<sup>+</sup> channel open probability by phosphatidylinositol-4,5-bisphosphate. *J Neurosci* 2005;25:9825–9835.
22. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. *Epilepsia* 2000;41:28–33.
23. Wang HS, Brown BS, McKinnon D, et al. Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. *Mol Pharmacol* 2000;57:1218–1223.
24. Boehm S, Betz H. Somatostatin inhibits excitatory transmission at rat hippocampal synapses via presynaptic receptors. *J Neurosci* 1997;17:4066–4075.
25. Nusser Z, Mody I. Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells. *J Neurophysiol* 2002;87:2624–2628.
26. Yeung JYT, Canning KJ, Zhu G, et al. Tonically activated GABAA receptors in hippocampal neurons are high-affinity, low-conductance sensors for extracellular GABA. *Mol Pharmacol* 2003;63:2–8.
27. Martire M, Castaldo P, D’Amico M, et al. M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. *J Neurosci* 2004;24:592–597.
28. Feng H-J, Botzolakis EJ, Macdonald RL. Context-dependent modulation of alphabeta4gamma2 and alphabeta2delta2 GABA A receptors by penicillin: implications for phasic and tonic inhibition. *Neuropharmacology* 2009;56:161–173.
29. Hoesgaard-Jensen K, Dalby NO, Wolinsky TD, et al. Pharmacological characterization of a novel positive modulator at alpha 4 beta 3 gamma2 delta-containing extrasynaptic GABA(A) receptors. *Neuropharmacology* 2010;58:702–711.
30. Mortensen M, Smart TG. Extrasynaptic alphabeta2delta3 subunit GABAA receptors on rat hippocampal pyramidal neurons. *J Physiol* 2006;577:841–856.
31. Sieghart W, Sperk G. Subunit composition, distribution and function of GABAA(A) receptor subtypes. *Curr Top Med Chem* 2002;2:795–816.
32. Ferron GM, Paul J, Fruncillo R, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. *J Clin Pharmacol* 2002;42:175–182.
33. Sotty F, Damgaard T, Montezinho LP, et al. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic
acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J Pharmacol Exp Ther 2009;328:951–962.

34. Ferando I, Mody I. GABAA receptor modulation by neurosteroids in models of temporal lobe epilepsies. Epilepsia 2012;53(Suppl. 9):89–101.

35. Walker MC, Kullmann DM. Tonic GABAA receptor-mediated signaling in epilepsy. In Noebels J, Avoli M, Rogwaski M, Olsen R, Delgado-Escueta A (Eds) Jasper’s basic mechanisms of the epilepsies. 4th Ed. Bethesda, MD: NCBI Bookshelf online book version, 2012:1–13.

36. Sun Y, Wu Z, Kong S, et al. Regulation of epileptiform activity by two distinct subtypes of extrasynaptic GABAA receptors. Mol Brain 2013;6:21.

37. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res 2013;103:2–30.

38. Cope DW, Di Giovanni G, Fyson SJ, et al. Enhanced tonic GABAA inhibition in typical absence epilepsy. Nat Med 2009;15:1392–1398.